首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KITLG |
| Uniprot No | P21583 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-189aa |
| 氨基酸序列 | EGICRNRVTNNVKDVTKLVANLPKDYMITLKYVPGMDVLPSHCWISEMVVQLSDSLTDLLDKFSNISEGLSNYSIIDKLVNIVDDLVECVKENSSKDLKKSFKSPEPRLFTPEEFFRIFNRSIDAFKDFVVASETSDCVVSSTLSPEKDSRVSVTKPFMLPPVA |
| 预测分子量 | 48.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KITLG(干细胞因子，SCF)重组蛋白的示例参考文献(内容为虚构示例，建议通过学术数据库查询真实文献)：
1. **文献名称**：*Recombinant human stem cell factor (KITLG) enhances hematopoietic recovery in irradiated mice*
**作者**：Smith A, et al.
**摘要**：研究重组人KITLG蛋白对辐射损伤小鼠造血系统的修复作用，证明其通过激活c-Kit受体促进造血干细胞增殖与分化。
2. **文献名称**：*Structural and functional analysis of KITLG recombinant protein variants in melanoma progression*
**作者**：Chen L, et al.
**摘要**：比较不同重组KITLG蛋白变体在黑色素瘤细胞迁移中的作用，发现特定结构域突变影响其与受体的结合能力及促癌信号传导。
3. **文献名称**：*KITLG recombinant protein promotes primordial germ cell survival in vitro*
**作者**：Tanaka Y, et al.
**摘要**：探讨重组KITLG在体外培养中对原始生殖细胞的保护机制，证实其通过PI3K/AKT通路抑制细胞凋亡。
4. **文献名称**：*Engineering a thermostable KITLG recombinant protein for therapeutic applications*
**作者**：Johnson R, et al.
**摘要**：报道一种通过蛋白质工程改造的高稳定性KITLG重组蛋白，优化其在体内半衰期及治疗骨髓衰竭疾病的潜力。
---
注：以上为模拟内容，实际文献需通过PubMed、Web of Science等平台检索关键词(如"recombinant KITLG protein"或"recombinant SCF")。
**Background of KITLG Recombinant Protein**
KIT ligand (KITLG), also known as stem cell factor (SCF) or steel factor, is a critical cytokine that binds to the c-Kit receptor tyrosine kinase, playing pivotal roles in hematopoiesis, gametogenesis, melanocyte development, and mast cell regulation. Discovered in the 1990s, KITLG exists in both membrane-bound and soluble forms, generated via alternative splicing. The membrane-bound form supports cell-cell interactions, while proteolytic cleavage releases soluble KITLG, enabling systemic signaling.
Recombinant KITLG protein is produced using biotechnological platforms (e.g., bacterial, mammalian, or insect cell systems) to ensure proper post-translational modifications, particularly dimerization essential for receptor activation. Its production involves cloning the *KITLG* gene into expression vectors, followed by purification via affinity chromatography.
As a research tool, recombinant KITLG is widely used to study cell proliferation, differentiation, and survival mechanisms in stem/progenitor cells. It is crucial in *ex vivo* expansion protocols for hematopoietic stem cells (HSCs) in transplantation and regenerative medicine. Clinically, KITLG-c-Kit signaling is implicated in cancers (e.g., gastrointestinal stromal tumors) and inflammatory disorders, making it a therapeutic target. Conversely, recombinant KITLG has therapeutic potential for treating conditions like anemia or germ cell deficiencies.
Despite its benefits, dysregulated KITLG signaling may promote tumor growth, underscoring the need for context-specific therapeutic strategies. Ongoing research focuses on optimizing recombinant KITLG for clinical applications while exploring its dual roles in health and disease.
×
